The global Cell Line Development Industry is poised for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period. According to the latest market insights, total cell line product sales are expected to reach US$ 3,124.4 million in 2023, and a staggering US$ 4,674.8 million by 2033. In 2022, the market for cell line development was valued at US$ 3,007.3 million, with an anticipated year-on-year growth of 3.9% in 2023.
This robust growth trajectory signifies a promising outlook for the Cell Line Development Market, driven by advancements in biotechnology, pharmaceutical research, and biomanufacturing processes. The demand for cell lines in drug development, vaccine production, and therapeutic research is surging, paving the way for substantial market expansion.
Click Here to Access Your Visuals-Packed Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-7566
Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.
In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST).
Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.
The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.
Journey to Excellence: Unlock Insights with Expert Guidance! https://www.futuremarketinsights.com/ask-question/rep-gb-7566
Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.
Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.
Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market.
Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gaucher’s disease, which is a genetic disorder characterized by lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body. For example Under cell line type segment in cell line development market, recombinant cell line development are the most demanding type of cell line due to large application in biologics production, protein interaction, gene activation, toxicity testing and drug screening.
Enhance Your Knowledge by Clicking the Link Provided https://www.futuremarketinsights.com/reports/brochure/rep-gb-7566
Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period
North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market.
The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.
FMI’s report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.
Key Market Segments Covered in Cell line development Market Research By Product Type:
- Reagent and Media
- Equipment
- Accessories and consumables
By Source Type:
- Mammalian cell line
- Non-mammalian cell line
By End User:
- Biopharmaceutical Companies
- Contract Research Organizations
- Academics and Research Institutes
- Biotechnology Companies
By Cell Lines:
- Recombinant cell lines
- Hybridomas
- Continuous cell lines
- Primary cell lines
Author
Sabyasachi Ghosh (Associate Vice President at Future Industry Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Industry Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Industry Insights (FMI)
Future Industry Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the Industry. FMI stands as the leading global provider of Industry intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals Industrys. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Industry Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futureIndustryinsights.com
Website: https://www.futureIndustryinsights.com
LinkedIn| Twitter| Blogs | YouTube